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Background: Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for
unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date,
the efficacy has been mostly assessed in the limited setting of phase II trials, and few attempts have been made to synthesise all
available data for survival outcomes.
Methods: Electronic databases were searched from 1980 to 2011. Survival results were combined for each pre-specified category
of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known
prognostic factors.
Results: A total of 32 studies were included for meta-analysis. Tendency towards better survival outcome by platinums or taxanes
was indicated. After adjustment for important prognostic factors, however, the difference between the platinum-based and non-
platinum regimens became no longer significant. Survival benefits by the taxane-based regimens remained significant, with a
prolonged median survival time of 1.52 months (P¼ 0.03) and a higher 1-year survival rate of 6.25% (P¼ 0.05), but the benefit did
not sustain for 2 years.
Conclusion: Although no effective therapies have been established, this meta-analysis helps to fill an important gap of evidence.
However, caution should still be taken because of the potential unmeasured confounding.
The European Society for Medical Oncology guideline lists
recommended chemotherapeutic approaches containing platinums
and taxanes as commonly used low-toxicity chemotherapy
regimens, but stated that no evidence exists for superior efficacy
of any of the administered regimens for unfavourable carcinoma of
unknown primary (CUP) patients (Fizazi et al, 2011). Although
CUP is a relatively common metastatic cancer constituting 3–5% of
all human malignancies (McCredie et al, 1991; Levi et al, 2002), the
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prognosis of CUP is very poor, with a median survival of 3–4
months, and its 5-year survival rate is o10% (Abbruzzese et al,
1994). Certain CUPs, which are defined as favourable prognostic
subsets, show a biology and behaviour similar to known metastatic
primary carcinoma (Greco and Pavlidis, 2009). However, patients
in the favourable subset constitute only a minority of CUP cases
and most patients remain unresponsive to any treatment
modalities and have a worse prognosis. As no effective therapies
have been established through randomised controlled trials (RCTs)
for such patients, empirical systemic treatments considering the
performance status of patients are widely accepted.
Some efforts for quantitative integration of survival outcomes of
previous clinical studies have been made. A descriptive summary
estimated a 9-month median survival time for platinum-based
chemotherapy by simply taking the median of the included studies’
quoted median survival times (Pentheroudakis et al, 2009). A
recent multiple treatment comparison meta-analysis based on a
small number of RCTs on chemotherapy regimens in unfavourable
CUP patients reported great uncertainty about the survival benefit
of any particular regimen (Golfinopoulos et al, 2009). As the
efficacy of chemotherapy for patients with unfavourable CUP has
mostly been assessed in the setting of small phase II trials without
controls, data from limited numbers of RCTs are insufficient
evidence for the superiority of any particular regimen in terms of
survival prolongation. Another meta-analysis that combined the
response rate from 29 phase II trials showed that the chemother-
apeutic regimens were not the sole significant parameters and
recommended multivariate analysis to consider the heterogeneity
of prognostic factors of previous CUP trials (Adenis et al, 2010).
Thus, this study critically evaluated all relevant studies on
chemotherapeutic approaches to unfavourable CUPs, which were
mostly from single-arm phase II trials, and evaluated whether
platinum- or taxane-based regimens could improve survival in
patients from the unfavourable subset of CUPs adjusting for some
known prognostic factors.
METHODS
Search strategy. Ovid MEDLINE, EMBASE, and the Cochrane
Central Register of Controlled Trials were searched comprehen-
sively without language restrictions, with hand searches for further
references. The search period was from 1980, when platinum was
introduced into the market, to 2011.
We first searched a combination of keywords: (cancer OR
carcinoma OR malignancy OR tumour OR neoplasm) AND
(unknown primary OR occult primary OR unknown origin) AND
(therapy OR therapeutic OR intervention). A team of reviewers in
pairs screened the title and abstract of each article. Any
discrepancies in the screening were resolved by re-evaluation and
discussion. Each full text of the articles selected by the screening
was then reviewed to determine its final inclusion.
Inclusion and exclusion criteria. Studies on chemotherapy for
the unfavourable subset of CUP were included. Literature on the
favourable subsets, such as papillary adenocarcinoma of the
peritoneal cavity in women, poorly differentiated carcinoma with
a midline distribution, poorly differentiated neuroendocrine
carcinomas, adenocarcinoma involving only the axillary lymph
nodes in women, squamous cell carcinoma involving cervical
lymph nodes, blastic bone metastases and elevated prostate-specific
antigen in men, and a single, small, potentially resectable tumour,
were excluded. For the diagnosis of CUP, included studies had to
evaluate the origin of metastasis at least by abdominal compu-
terised tomography (CT) with either chest CT or plain chest
radiography. Phase II and phase III clinical trials were included
and consecutive case series performed with the prospective
enrolment of participants following clear inclusion criteria were
considered for inclusion. Studies evaluating alternating regimens
before disease progression or on second-line chemotherapy were
excluded. Duplicate publications were excluded by retaining the
one with the longest follow-up or the one that reported the data
more comprehensively.
Quality assessment. The Methodological Index for Non-Rando-
mised Studies (MINORS) (Slim et al, 2003) was adopted for quality
assessment and applied primarily to all the included studies.
Assessments for the Risk of Bias were also conducted for the RCTs
using the Cochrane guideline (Higgings, 2008).
Data extraction. A pair of reviewers independently extracted
relevant data from the studies using a standardised data extraction
form. Information on the type of study design, patient follow-up,
prognostic factors, chemotherapeutic regimens, and survival out-
comes was abstracted. The survival outcomes were extracted using
the methods of Tierney et al (2007), and confidence intervals were
calculated based on the method of Simon (1986).
Statistical analysis. We first explored a combined estimate of
survival outcome for each pre-specified regimen group: platinum
vs no-platinum; taxane vs no-taxane; platinum and taxane (P1T1)
vs platinum and no-taxane (P1T0) vs no-platinum and taxane
(P0T1) vs no-platinum and no-taxane (P0T0). The outcomes
considered were the median survival time, and the 1- and 2-year
survival rates.
We pooled the results of each outcome for each category by the
inverse variance method to generate a crude overall summary with
a 95% confidence interval (95% CI) and descriptively contrasted
the point estimates between categories. A multiple meta-regression
model was then built up for testing the significance of the
differences between platinum and no-platinum; taxane and no-
taxane; and each of P1T1, P1T0, P0T1, and P0T0 after adjustment for
covariates. Being male, a histology of moderate- to well-
differentiated adenocarcinoma, poor Eastern Cooperative Oncol-
ogy Group (ECOG) performance status (X2), liver metastasis, and
multiple metastatic sites were considered potentially important
prognostic factors (Pavlidis and Fizazi, 2005). The year of the study
could also influence survival outcomes and was considered a
potential source of heterogeneity.
A random-effects model was applied to combine the outcomes.
The statistical heterogeneity among the studies was evaluated
qualitatively with a forest plot as well as quantitatively with the I2
measure and w2 test. The funnel plots asymmetry was assessed for
small study effects.
RESULTS
Description of the included studies. A total of 1389 potentially
relevant studies, 1385 from the electronic search and four from the
hand searches, were identified, and 1281 were excluded by title/
abstract screening. Full texts were retrieved for the remaining 108
studies, and 32 of them met all the criteria for inclusion in the
analysis (Figure 1).
There were seven RCTs (Shildt et al, 1983; Dowell et al, 2001;
Assersohn et al, 2003; Culine et al, 2003; Palmeri et al, 2006;
Huebner et al, 2009; Hainsworth et al, 2010) and one non-
randomised trial (Saghatchian et al, 2001) where two treatment
arms were evaluated. Six of the included clinical trials primarily
explored or estimated the treatment outcome separately; only one
phase III trial had a primary objective of directly comparing the
two treatment regimens (Hainsworth et al, 2010). Another phase
III trial identified by electronic search was excluded because only
the abstract was accessible and contacting the author yielded no
further information (Gross-Goupil et al, 2009). Both the phase III
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trials were stopped before enrolment of the planned sample size
because of slow accrual.
There was one consecutive case series study (Gill et al, 1991)
and the other 23 studies were single arm clinical trials (Raber et al,
1991; Briasoulis et al, 1998, 2000, 2008; Parnis et al, 2000; Greco
et al, 2001, 2002; Guardiola et al, 2001; Macdonald et al, 2002;
Balana et al, 2003; Mukai et al, 2003, 2010; Park et al, 2004; Piga
et al, 2004; Pouessel et al, 2004; El-Rayes et al, 2005; Pittman et al,
2006; Schneider et al, 2007; Pentheroudakis et al, 2008; Hainsworth
et al, 2009; Schuette et al, 2009; Yonemori et al, 2009; Moller et al,
2010). Three trials (Briasoulis et al, 1998, 2000; Pentheroudakis
et al, 2008) also involved a small proportion of favourable CUP
patients in their studies, and we extracted the data only from the
unfavourable subset.
In the quality assessment using MINORS, most studies scored
X10 points; however, three studies conducted before 2000 scored
o10 (Shildt et al, 1983; Raber et al, 1991; Parnis et al, 2000). Two
independent reviewers evaluated the responses, which were the
primary outcome of the study in only two studies (Culine et al,
2003; Moller et al, 2010). In all, 14 studies reported prospective
calculation of the study size (Greco et al, 2002; Macdonald et al,
2002; Pouessel et al, 2004; El-Rayes et al, 2005; Palmeri et al, 2006;
Pittman et al, 2006; Schneider et al, 2007; Pentheroudakis et al,
2008; Hainsworth et al, 2009, 2010; Huebner et al, 2009; Schuette
et al, 2009; Yonemori et al, 2009; Mukai et al, 2010). Among the
RCTs, only one study had a clear description of the method of
allocation concealment (Assersohn et al, 2003). No RCT was
blinded; however, we did not consider it a major threat to the
validity since the outcomes should not be influenced by blinding.
Among the 42 regimens investigated, 35 were evaluated in
studies conducted since 2000. In all, 26 regimens were tested based
on a sample of 30 to 60 patients. The proportions of male patients
in most of the studies were 50–75%. The efficacy of 14 regimens
was tested with patients among whom 50–75% had moderate- to
well-differentiated adenocarcinoma, and 13 regimens with patients
among whomo50% had the histological attribute. The proportion
of patients with liver metastasis waso50% in 17 regimens. A total
of 24 regimens were assessed with patients among whom o20%
had an ECOG performance status X2. The proportion of patients
with multiple metastases was 50–75% in 21 regimens. Only two
regimens out of 42 were monotherapies; 34 regimens contained
platinums and 17 included taxanes. Only one regimen had a
follow-up duration shorter than 12 months, and 29 regimens were
followed for longer than 24 months. The examined regimens and
prognostic profiles are summarised in Table 1.
Survival estimation by regimen groups. The combined results by
regimen group, 95% CIs, and statistics for heterogeneity are shown
in Figure 2. The overall median survival time was 9.0 months (95%
CI: 8.1–9.8), 1-year survival rate 35.6% (95% CI: 32.0–39.3), and 2-
year survival rate 18.6% (95% CI: 15.4–21.7) across all chemother-
apy regimens.
Most regimens (34 out of 42) contained a platinum component,
demonstrating that using platinum in CUP treatment has become
common. The majority of platinums were cisplatin or carboplatin,
and oxaliplatin was used in only 2 out of the 34 regimens. For the
meta-analysis, 26 regimens were included in the platinum group
and 6 regimens in the non-platinum group. The platinum-based
regimens showed a tendency to have better outcomes in the
survival: median survival time of 9.4 vs 7.2 months; 1-year survival
rate of 36.9% vs 29.6%; 2-year survival rate of 19.7% vs 11.9% for
the platinum regimens vs non-platinum regimens.
When 16 taxane regimens and 16 non-taxane regimens were
each combined, a slightly longer median survival (9.6 months) was
estimated for the taxane regimens overall than the non-taxane
regimens (8.3 months). A greater 1-year survival rate (41.3% vs
30.8%) was observed for the taxane group, and there was no
overlapping of 95% CIs between the taxane group and the non-
taxane group. However, the tendency towards better results in the
taxane group was no longer definite but was sustained for the 2-
year survival rate (21.2% vs 16.4%).
Among 14 P1T1, 12 P1T0, 2 P0T1, and 4 P0T0 regimens, we
found P1T1 was the best regimen group and P0T0 was the worst for
all survival outcomes. While a small number of studies were
included, P0T1 tended to be better than P1T0 for median survival
time (9.5 vs 8.9 months) and 1-year survival rate (36.6% vs 32.1%).
Investigation of heterogeneity. No significant association was
found between the study year and outcomes shown by meta-
regression analyses (Table 2). In the univariable meta-regression,
the median survival was related to the histology and ECOG
performance status. The 1- and 2-year survival probabilities were
Relevant studies by search strategy
Electronic search (n =1385)
Hand search (n =4)
1281 studies not eligible judged by title
and abstract (e.g. specific organ origin,
or treatment modality other than chemotherapy)
• Head and neck squamous cell carcinoma: 15
• Inclusion of non-CUP patients: 1
• No description on diagnosis criteria: 15
• No abdominal CT: 20
• No imaging study for lung: 1
• Alternating treatment: 3
• Second-line treatment: 6
• Reviews: 3
• Non-consecutive case series: 2
• Duplicate publication: 10
Full text reviewed (n =108)
Quality evaluation (n =32)
Figure 1. Flow chart of literature selection.
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Table 1. The chemotherapeutic regimens and major prognostic factors of the studies included
Major prognostic factors, N (%)
Author and year
of study
Regimens N Male
sex
MWD ECOG
X2
Liver
meta
Multiple
meta
Follow-up
(months)
Shildt et al (1983) 5-Fluorouracil 20 — — — — 10.2
Shildt et al (1983) Cyclophosphamide, 5-fluorouracil,
doxorubicin
16 — — — — — 24.5
Raber et al (1991) Cisplatin, 5-fluorouracil, etoposide 46 — 26 (56.5) 2 (4.3) — — —
Gill et al (1991) Cisplatin, etoposide 16 9 (56.3) 6 (37.5) — 5 (31.3) 10 (62.5) 28.75
Briasoulis et al (1998) Carboplatin, etoposide, epirubicin 45 — — — — — 40
Parnis et al (2000) Cisplatin, 5-fluorouracil, epirubicin 43 27 (62.8) — 7 (16.3) 16 (37.2) 31 (72.1) 54
Briasoulis et al (2000) Carboplatin, paclitaxel 33 18 (54.5) 22 (66.7) — — — 47
Dowell et al (2001) Carboplatin, etoposide 17 10 (58.8) 14 (82.4) 6 (35.3) 11 (64.7) 11 (64.7) 17.3
Dowell et al (2001) Paclitaxel, 5-fluorouracil, leucovorin 17 10 (58.8) 11 (64.7) 3 (17.6) 10 (58.8) 10 (58.8) 16
Guardiola et al (2001) Cisplatin, doxorubicin, cyclophosphamide 22 13 (59.1) 8 (36.4) — 6 (27.3) 12 (54.5) 56.9
Greco et al (2001) Carboplatin, paclitaxel, etoposide 71 35 (49.3) 34 (47.9) 12 (16.9) — 43 (60.6) 50
Greco et al (2001) Cisplatin, docetaxel 26 13 (50.0) 13 (50.0) 6 (23.1) — 19 (73.1) 33
Greco et al (2001) Carboplatin, docetaxel 47 25 (53.2) 18 (38.3) 12 (25.5) — 32 (68.1) 24
Saghatchian et al (2001) Cisplatin, etoposide, ifosfamide,
bleomycin
30 15 (50.0) 0 (0) 7 (23.3) 3 (10) 17 (56.7) 32
Saghatchian et al (2001) Cisplatin, 5-fluorouracil, interferon 18 6 ( (33.3) 18 (100) 1 (5.6) 6 (33.3) 8 (44.4) 32
Macdonald et al (2002) Cisplatin, 5-fluorouracil, mitomycin 31 18 (58.1) 22 (71.0) 5 (16.1) 7 (22.6) 16 (51.6) 53
Greco et al (2002) Carboplatin, paclitaxel, gemcitabine 120 64 (53.3) 63 (52.5) 16 (13.3) 51 (42.5) 78 (65) 27
Culine et al (2003) Cisplatin, gemcitabine 39 26 (66.7) 26 (66.7) 6 (15.4) 21 (53.8) 29 (74.4) 22
Culine et al (2003) Cisplatin, irinotecan 40 18 (45.0) 24 (60.0) 7 (17.5) 21 (52.5) 30 (75.0) 22
Assersohn et al (2003) 5-Fluorouracil 45 28 (62.2) 15 (33.3) 12 (26.7) 30 (66.7) 22 (48.9) 24
Assersohn et al (2003) 5-Fluorouracil, mitomycin 43 20 (46.5) 18 (41.9) 15 (34.9) 21 (48.8) 17 (39.5) 24
Balana et al (2003) Cisplatin, gemcitabine, etoposide 40 25 (62.5) 15 (37.5) 4 (10.0) 6 (15.0) 27 (67.5) 29
Mukai et al (2003) Cisplatin, docetaxel 5 1 (20.0) 4 (80.0) 1 (20.0) — — —
Piga et al (2004) Carboplatin, etoposide, doxorubicin 102 54 (52.9) 38 (37.3) 8 (7.8) 27 (26.5) 89 (87.3) 60
Pouessel et al (2004) Docetaxel, gemcitabine 36 23 (63.9) 16 (44.4) 3 (8.3) 15 (41.7) 26 (72.2) 32
Park et al (2004) Cisplatin, paclitaxel 37 20 (54.1) 31 (83.8) 8 (21.6) 12 (32.4) 35 (94.6) 31.5
El-Rayes et al (2005) Carboplatin, paclitaxel 22 13 (59.1) 15 (68.2) 2 (9.1) 17 (77.3) — 23.2
Palmeri et al (2006) Cisplatin, paclitaxel, gemcitabine 33 25 (75.8) 25 (75.8) 1 (3.0) 8 (24.2) 14 (42.4) 20.5
Palmeri et al (2006) Cisplatin, gemcitabine, vinorelbine 33 27 (81.8) 23 (69.7) 1 (3.0) 10 (30.3) 15 (45.5) 21.5
Pittman et al (2006) Carboplatin, gemcitabine 50 23 (46.0) — 12 (24.0) 38 (76.0) — 35
Schneider et al (2007) Carboplatin, gemcitabine, capecitabine 33 19 (57.6) 22 (66.7) 9 (27.3) 20 (60.6) 10 (30.3) 54.1
Pentheroudakis et al
(2008)
Carboplatin, docetaxel 23 12 (52.2) — 3 (13.0) 9 (39.1) 13 (56.5) 48
Briasoulis et al (2008) Oxaliplatin, irinotecan 47 33 (70.2) 19 (40.4) 11 (23.4) 27 (57.4) 27 (57.4) 35.5
Huebner et al (2009) Carboplatin, paclitaxel 42 23 (54.8) — 5 (11.9) 23 (54.8) 36 (85.7) 26
Huebner et al (2009) Gemcitabine, vinorelbine 45 27 (60.0) — 10 (22.2) 29 (64.4) 37 (82.2) 22
Schuette et al (2009) Oxaliplatin, capecitabine 51 35 (68.6) 7 (13.7) 5 (9.8) 20 (39.2) — 24
Yonemori et al (2009) Carboplatin, irinotecan 45 23 (51.1) 21 (46.7) 4 (8.9) 8 (17.8) 32 (71.1) 48
Hainsworth et al (2009) Carboplatin, paclitaxel, bevacizumab,
erlotinib
60 29 (48.3) 31 (51.7) 0 — 30 (50.0) 25
Mukai et al (2010) Cisplatin, docetaxel 45 23 (51.1) 19 (42.2) 6 (13.3) — 10 (22.2) 57.1
Moller et al (2010) Cisplatin, paclitaxel, gemcitabine 98 51 (52.0) — 0 49 (50.0) 53 (54.1) 80
Hainsworth et al (2010) Carboplatin, paclitaxel, etoposide,
gefitinib
93 44 (47.3) 49 (52.7) 9 (9.7) 50 (53.8) 75 (80.6) 60
Hainsworth et al (2010) Gemcitabine, irinotecan, gefitinib 105 63 (60.0) 56 (53.3) 8 (7.6) 54 (51.4) 73 (69.5) 60
Abbreviations: MWD¼moderate- to well-differentiated adenocarcinoma; ECOG¼Eastern Cooperative Oncology Group performance status; meta¼metastasis.
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related to the gender, ECOG performance status, and whether liver
metastasis occurred.
Assessment of treatment differences by regimen. The differences
we observed in the descriptive comparison of the point estimates of
crude overall summaries by platinums became less noticeable and
tended to be null after adjustment of the prognostic factors
(Table 3). However, the difference in the median survival time by
the taxane-containing combination increased to 1.52 months after
adjustment for covariates and was statistically significant
(P¼ 0.03). The obvious superiority of the 1-year survival rate with
taxane-based regimens remained significant (P¼ 0.05), and a
0.0
P1
P0
T1
T0
P1T1
P1T0
P0T0
Total
0.0
0.0
10.0 20.0 30.0
32.8 36.9 41.1
37.6 41.3 44.9
35.729.623.5
35.730.825.8
45.441.6
38.732.125.5
20.4
21.1 27.6 34.1
39.3
23.219.716.2
18.711.95.2
17.6 21.2
16.4 21.211.6
18.6 22.3
11.3
0.0 7.0
5.8 13.6 21.5
15.4 18.6 21.7
20.3
17.4 23.6
26.0
24.8
35.632.0
36.6 52.8
37.8
10.05.0 15.0 25.020.0 30.0
34.5 23 0.04 36.2%
11.9 14 0.54 0%
22.0 13 0.04 45.4%
7.1 13 0.85 0%
21.3
— — —1
10 0.01
0.4
39.4 24
3 0.81 0%
0.05 34.0%
57.8%
1.2 4 0.77 0%
40.0 50.0 60.0
53.5 <0.01
65.5 0.36 8.5%
1612.7 0.63 0%
0%
16
14
30.0
10.9
0.01
0.62
49.9%
12
2
4
27.1
1.4
2.4
63.3 32 <0.01 51.0%
0.01
0.24
0.50
59.3%
28.3%
0.0%
P0T1
P1
P0
T1
T0
P1T1
P1T0
P0T0
Total
P0T1
P1
P0
T1
T0
P1T1
P1T0
P0T0
Total
P0T1
M
ed
ia
n 
su
rv
iva
l
1-
ye
a
r 
su
rv
iva
l
2-
ye
a
r 
su
rv
iva
l
2.0 6.0 8.0 10.0 12.0 14.0 2 n
59.7
8.4 9.4 10.3
8.9
8.4 9.6 10.8
8.3 9.6 11.0
9.48.37.2
10.2
9.5 12.86.2
4.7 6.6 8.5
8.1 9.0 8.8
8.97.6
7.25.5
8.1
26
6
<0.01 58.1%
38.3%0.15
0.01 53.9%
52.6%
59.8%
49.1%
0%
42.8%
0.01
<0.01
0.03
0.66
0.16
14
12
2
32.3
21.6
0.2
5.2
75.2 32 <0.01 58.8%
4
32.5
31.6
16
16
P l 2
2 n P l 2
2 n P l 2
4.0
Figure 2. Combined estimates for the survival by treatment strategy. w2, chi-squared statistics; n, the number of studies that were included to the
regimen groups, I2, I-squared statistics; P1, platinum; P0, no platinum; T1, taxane; T0, no taxane; P1T1, platinum and taxane; P1T0, platinum and no
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possible treatment difference of 6.25% remained. No statistically
significant survival benefit was observed from the comparison of
the regimens containing platinum, taxane, or both to the
chemotherapies with agents other than platinums or taxanes,
except for the marginal significance of regimens containing both
platinums and taxanes for a median survival time of 2.02 months
(P¼ 0.06). The results also suggest a decrease in the 2-year survival
rate by taxane regimens without a platinum agent, although it was
not statistically significant. The only regimens to have positive
results, although not reaching statistical significance, at all end
points are the regimens containing both platinum and taxane in
comparison to regimens containing neither of them.
Comparison of survival rates from randomised controlled
clinical trials. None of the five RCTs providing data for
calculating a comparative effect measure showed a hazard ratio
(HR) significantly different from one for the overall survival rate
(Figure 3). Apart from one out of the five studies, all studies
involved at least one regimen containing taxane or platinum.
Among the four studies comparing regimens containing taxane
with others without taxane, two of the studies showed a direction
of effect contrasting with the other two studies. The pooled HR was
0.95 (95% CI: 0.65–1.26), suggesting a nonsignificant difference. In
examining the regimens for comparison of platinum against non-
platinum, there was also heterogeneity in the direction of treatment
Table 2. Relationship between prognostic factors and survival outcomes
Characteristics Median survival 1-Year survival 2-Year survival
Coefficienta P-value Coefficienta P-value Coefficienta P-value
Year of the study  0.01 0.93  0.11 0.85 0.40 0.43
Gender 5.29 0.21 30.23 0.07b 31.71 0.02b
Histology 5.90 0.07b 21.19 0.18 10.24 0.44
ECOG performance  9.77 0.02b  62.17 o0.01b 33.62 0.05b
Liver metastasis  3.78 0.15  27.1 0.01b 26.61 o0.01b
Multiple metastasis  1.67 0.49 10.98 0.29 7.34 0.40
Abbreviation: ECOG¼Eastern Cooperative Oncology Group performance status.
aCoefficient represents a linear relationship between each prognostic factor and the survival outcome by a univariable meta-regression model. The sign of the coefficient indicates the positivity
or negativity of the relationship. The P-value of each coefficient indicates whether the linear correlation was significant or not.
bP-value o0.1.
Table 3. Difference between subgroups adjusting prognostic factors as appropriate
Outcomes Regimens Coefficient (95% confidence interval)a P-value
Median survival (months)b Platinum 0.76 (1.14 to 2.67) 0.43
Taxane 1.52 (0.12 to 2.92) 0.03
No-platinum, no-Taxane Reference
Platinum, no-Taxane 0.78 (1.16 to 2.72) 0.43
No-platinum, taxane 2.58 (1.09 to 6.26) 0.17
Platinum and taxane 2.02 (0.05 to 4.09) 0.06
1-Year survival (%)c Platinum 2.68 (10.95 to 5.58) 0.52
Taxane 6.25 (0.05 to 12.55) 0.05
No-platinum, no-taxane Reference
Platinum, no-taxane 2.93 (11.76 to 5.89) 0.52
No-platinum, taxane 8.28 (6.93 to 23.48) 0.29
Platinum and taxane 3.14 (6.47 to 12.76) 0.52
2-Year survival (%)c Platinum 2.21 (5.93 to 10.35) 0.60
Taxane 0.98 (5.58 to 7.53) 0.77
No-platinum, no-taxane Reference
Platinum, no-taxane 2.30 (12.04 to 7.43) 0.64
No-platinum, taxane 11.63 (28.04 to 5.63) 0.19
Platinum and taxane 0.01 (11.34 to 11.36) 0.99
Abbreviation: ECOG¼Eastern Cooperative Oncology Group performance status.
aThe coefficient from a multiple meta-regression model after adjustment for prognostic factors represents changes of the survival outcome by adding the particular agent(s) to a regimen in
comparison to one without them or to the reference.
bAdjusted for proportion of moderate- to well-differentiated adenocarcinoma, and proportion of performance status (in ECOG X2).
cAdjusted for proportion of male patients, proportion of performance status (in ECOG X2), and liver metastasis.
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effect, which produced a pooled HR of 0.99 (95% CI: 0.67–1.30).
For the comparison of regimens containing both taxane and
platinum against neither of them, there was a significant
heterogeneity between the two included results and they produced
a pooled HR of 0.92 (95% CI: 0.44–1.40).
Assessment for funnel plot asymmetry. We observed an asym-
metric funnel plot in only the median survival time (P¼ 0.05), but
no apparent trend in the 1- or 2-year survival rate. The former
indicated an association between the treatment results and study
size (Figure 4). We performed the Egger test for the median
survival time stratified by taxanes and platinums. The small study
effect was more salient in the platinum regimens (P¼ 0.04) than
non-platinum regimens (P¼ 0.33) and in non-taxane regimens
(P¼ 0.10) than taxane regimens (P¼ 0.96).
DISCUSSION
An important target of treating cancer patients should be
prolonging survival. However, for the unfavourable subset of
CUP patients, there has been no clear understanding of the survival
benefits by any chemotherapeutic treatment so far, although
platinum- or taxane-based regimens have been commonly and
empirically used in current clinical practice. The aim of our study
was to estimate the survival efficacy of those regimens by
systematically evaluating all relevant data in the literature.
In a recently issued guidance by the National Institute for
Health and Clinical Excellence on metastasis with unknown
primary, a combination of carboplatin and paclitaxel was suggested
to have the highest total expected quality-adjusted life years among
the therapeutic approaches, but the probability that the combina-
tion was cost-effective was o50% at a given willingness to pay
threshold in current UK clinical practice (Fowell, 2010; MacReady,
2010). The guidance also indicated a lack of information
supporting any particular chemotherapy in terms of survival
prolongation in patients with CUP not belonging to a specific
favourable group in the currently available literature. Our study
suggested that the addition of a taxane to the regimen extended the
median survival time by 1.52 months (95% CI: 0.12–2.92) and
increased the 1-year survival rate by 6.25% (95% CI: 0.05–12.55).
Although the survival benefit did not remain for 2 years, the
suggested improvement in the median survival time and the 1-year
survival probability, accounting for the heterogeneous settings, can
provide clinically meaningful evidence of the survival benefit by
including taxane in combinatorial chemotherapy.
The majority of platinums in the included regimens were
cisplatin or carboplatin, but oxaliplatin was also used in 2 out of
the 34 platinum regimens. Oxaliplatin has a particular indication
(Cvitkovic, 1998; Graham and Cassidy, 2012) and may better be
considered separately from other platinum agents in clinical use,
whereas cisplatin and carboplatin can, for the most part, substitute
for each other. For this reason, we conducted a reanalysis by
removing the two oxaliplatin regimens from the platinum group,
which had little impact on the results but a slight shift towards
increasing survival: median survival time from 9.4 months (95%
CI: 8.4–10.3) to 9.5 months (95% CI: 8.5–10.5); 1-year survival rate
from 36.9% (95% CI: 32.8–41.1) to 38.9% (95% CI: 35.9–42.0); and
2-year survival rate from 19.7% (95% CI: 16.2–23.2) to 20.7% (95%
CI: 17.9–23.6). Consequently, the differences between subgroups
presented in Table 3 were not influenced much by exclusion of
oxaliplatin from the platinum group.
Because RCTs provide another level of evidence, we also
analysed them separately by categorising them to assess the effects
of containing taxane, platinum, or both. Five RCTs were available
with data for calculation of HR. The categorised pooled results
suggested slightly favourable results toward taxane, platinum, or
both in comparison to regimens without any of them, but failed to
confirm the effect, mainly due to heterogeneity between the small
number of small-sized studies. A previous meta-analysis of RCTs
Year Ref.
All RCTs
Carboplatin paclitaxel etoposide gefitinib
Carboplatin paclitaxel etoposide gefitinib
Carboplatin paclitaxel etoposide gefitinib
Carboplatin paclitaxel etoposide gefitinib
Paclitaxel 5-fluorouracil leucovorin
Paclitaxel 5-fluorouracil leucovorin
Cisplatin paclitaxel gemcitabine
Cisplatin paclitaxel gemcitabine Cisplatin gemcitabine vinorelbine 1.25 (0.68–2.30) 33 33
93
42
17 17
4345
45
1051.17 (0.87–1.58)
0.68 (0.43–1.08)
0.89 (0.38–2.06)
0.83 (0.50–1.38)
1.25 (0.68–2.30) 33 33
93
42
17 17
45
42
17 17
45
105
93 105
1.17 (0.87–1.58)
1.13 (0.87–1.58)
1.17 (0.87–1.58)
0.68 (0.43–1.08)
0.68 (0.43–1.08)
42 45
93 1051.17 (0.87–1.58)
0.68 (0.43–1.08)
0.89 (0.38–2.06)
0.95 (0.65–1.26)
0.99 (0.67–1.30)
0.92 (0.44–1.40)
0 1 3
Cisplatin gemcitabine vinorelbine
Gemcitabine irinotecan gefitinib
Gemcitabine irinotecan gefitinib
Gemcitabine irinotecan gefitinib
Gemcitabine irinotecan gefitinib
Gemcitabine vinorelbine
Gemcitabine vinorelbine
Gemcitabine vinorelbine
Paclitaxal 5-fluorouracil leucovorin
Gemcitabine vinorelbine
Carboplatin etoposide
Carboplatin etoposide
5-fluorouracil mitomycin5-fluorouracil
Carboplatin paclitaxel
Carboplatin paclitaxel
Carboplatin paclitaxel
Cadboplatin paclitaxel
Carboplatin etoposide
Subtotal (I 2 = 60.4%, P = 0.080)
Subtotal (I 2 = 35.3%, P = 0.200)
Subtotal (I 2 = 74.9%, P = 0.046)
2006 14
20
18
19
16
2010
2009
2001
2003
2006 14
20
18
19
2010
2009
2001
20
18
19
2010
2009
20
18
2010
2009
2001
Treatment A Treatment B HR (95% CI) nA nB
Taxane vs non-taxane
Platinum vs non-platinum
Platinum and taxane vs non-platinum and non-taxane
Figure 3. Comparison of survival rates from the randomised controlled clinical trials. The hazard ratio above 1 means that the risk of death by the
first regimen is higher than that by the second regimen. nA, number of patients in the treatment A; nB, number of patients in the treatment B.
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conducted a multiple treatment comparison, a kind of indirect
comparison among different treatments using a Bayesian statistical
method, which also failed to demonstrate a survival benefit by any
chemotherapeutic regimen for CUP (Golfinopoulos et al, 2009).
The analysis also suggested that the hazard ratios favoured
platinum (0.69, 95% CI: 0.39–1.28); taxane (0.66, 95% CI: 0.22–
2.08); or both (0.81, 95% CI: 0.34–1.89), in comparison with a
monotherapy regimen with an agent other than platinum or
taxane. Their analysis included a larger number of RCTs because of
less restrictive inclusion criteria applied, in terms of method of
diagnosis for CUP, than those used in our study. Their results also
suggested a great uncertainty with a wider Bayesian version of CIs.
Lack of a large enough number of RCTs, especially for phase III,
could be a possible explanation of the failure to demonstrate
significance, although the possible efficacy of taxane or platinum
was suggested consistently. From the five trials included in our
meta-analysis of RCTs, only one trial was a study conducted to
evaluate a comparative efficacy in the setting of phase III, but the
study also stopped early because of slow accrual of patients. The
other trials were randomised studies, but still were phase II studies,
which aimed to assess efficacy in each treatment arm rather than
for investigating a comparative efficacy. In such a circumstance,
this study is of importance by filling the lack of certainty in the
current evidence by utilising all available information with a
maximum control of incomparability.
The funnel plot of the median survival showed an asymmetry
indicating a small study effect. The scatter plot of survival outcome
against its standard error is supposed to have a symmetric shape of
an inverse funnel, representing a wide variability of estimates from
small studies and narrow range of those from large studies. Thus,
emptiness in the left base of the funnel suggests that small studies
have a tendency to report favourable outcomes, which is referred as
the small study effect and is often interpreted as an indication of
publication bias. However, it is also a common phenomenon in the
early development of a new treatment (Lau et al, 2006). The
observed small study effect in the current analysis may also be due
to such a true heterogeneity (Higgings, 2008), as a short-term
benefit from chemotherapy is more likely in patients with high-
performance status for tolerating toxicity of the treatment and such
patients are more likely to be included in small, early phase clinical
trials in the development of new treatment regimens. The stratified
funnel plots and Egger test results suggest that the small study
effect was more noticeable in the non-taxane or platinum
regimens, which may imply that the survival benefits by taxanes
were estimated rather conservatively, while those by platinum were
still nonsignificant even with possible overestimation.
Our study results should be interpreted with caution because of
several limitations. In this setting, a selection of studies with similar
populations is particularly difficult, because of the heterogeneous
nature of the CUP population, the availability of mostly single
institute-based small studies, and the long interval from which the
studies were selected. Although we tried to adjust for the
differences in known prognostic factors among studies using a
meta-regression in the evaluation of the treatment effect, the
limitation of this study is that comparisons between those studies
can barely substitute for RCTs even after correction for some
characteristics across trials. This meta-analysis could still be
susceptible to some bias from unmeasured confounders potentially
influencing the overall survival, for example, palliative care offered
or second-line treatment. Since the included studies have been
conducted over a couple of decades, the identification of treatable
subsets has changed during the time, which may also cause such
heterogeneity as an unmeasurable confounder. Many of the trials,
particularly in the first decade, contained some patients who would
currently be identified and treated with regimens other than
empiric therapy. On the other hand, a significant improvement in
the supportive care and the health-care system can also influence
the outcomes of the treatments. Most of the included studies were,
in fact, found to be carried out within the past decade, and such an
evolution effect might therefore have been minimised. We indeed
observed lack of a relationship between the survival outcomes and
the year of the study (Table 2).
The potential limitations notwithstanding, our study showed
that combinations containing a taxane agent demonstrated a
prolongation of the median survival time and higher 1-year
survival rate in the first-line treatment of unfavourable CUP
compared with those without taxanes. However, such a benefit did
not seem to be sustained for 2 years. Summaries of available RCTs
suggested addition of platinum, taxane, or platinum and taxane to
a regimen tends to extend survival of CUP patients; however, those
findings based on RCTs were said to be very uncertain owing to a
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Figure 4. Funnel plot for evaluation of the small trial effect for survival.
The fitted line corresponds to the regression test for funnel plot
asymmetry proposed by Egger et al (1997).
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so small number of RCTs. This systematic review and meta-
analysis utilising all available clinical trials fills an important gap of
certainty in the current evidence by demonstrating a beneficial
effect in the use of taxane for unfavourable CUP patients.
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